A multi-targeting pre-clinical candidate against drug-resistant tuberculosis

Parvinder Kaur*, Vijay Potluri, Vijay Kamal Ahuja, C. N. Naveenkumar, Ramya Vadageri Krishnamurthy, Shruthi Thimmalapura Gangadharaiah, Prasad Shivarudraiah, Sumesh Eswaran, Christy Rosaline Nirmal, Balasubramanian Mahizhaveni, Azger Dusthackeer, Rajesh Mondal, Sarah M. Batt, Emily J. Richardson, Nicholas J. Loman, Gurdyal Singh Besra, Radha Krishan Shandil, Shridhar Narayanan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


FNDR-20081 [4-{4-[5-(4-Isopropyl-phenyl)- [1,2,4]oxadiazol-3-ylmethyl]-piperazin-1-yl}-7-pyridin-3-yl-quinoline] is a novel, first in class anti-tubercular pre-clinical candidate against sensitive and drug-resistant Mycobacterium tuberculosis (Mtb). In-vitro combination studies of FNDR-20081 with first- and second-line drugs exhibited no antagonism, suggesting its compatibility for developing new combination-regimens. FNDR-20081, which is non-toxic with no CYP3A4 liability, demonstrated exposure-dependent killing of replicating-Mtb, as well as the non-replicating-Mtb, and efficacy in a mouse model of infection. Whole genome sequencing (WGS) of FNDR-20081 resistant mutants revealed the identification of pleotropic targets: marR (Rv0678), a regulator of MmpL5, a transporter/efflux pump mechanism for drug resistance; and Rv3683, a putative metalloprotease potentially involved in peptidoglycan biosynthesis. In summary, FNDR-20081 is a promising first in class compound with the potential to form a new combination regimen for MDR-TB treatment.

Original languageEnglish
Article number102104
Publication statusPublished - Jul 2021
Externally publishedYes

Bibliographical note

Funding Information:
This study was funded by Foundation for Neglected Disease Research.

Funding Information:
The authors would like to acknowledge Mr. Mayas Singh from FNDR for facilitating the project activities.

Publisher Copyright:
© 2021 Elsevier Ltd


  • Drug resistance
  • First-in-class
  • Multi-target
  • Mycobacterium tuberculosis
  • Pre-clinical candidate


Dive into the research topics of 'A multi-targeting pre-clinical candidate against drug-resistant tuberculosis'. Together they form a unique fingerprint.

Cite this